Jon S Odorico, MD

Professor

  • Section of Kidney and Pancreas Surgery
  • Division of Transplantation

jon@surgery.wisc.edu
(608) 263-0388

Clinical Science Center
600 Highland Avenue
Madison WI 53792

Education

  • MD, New York University, School of Medicine, New York, NY, 1987
  • Residency, General Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 1987-1994
  • Postdoctoral Research Fellow, Harrison Department of Surgical Research, Hospital of the University of Pennsylvania, Philadelphia, PA, 1990-1992
  • Fellow, Transplant Surgery, University of Wisconsin Hospital and Clinics, Madison, WI, 1994-1996

Clinical Specialties

Dr. Odorico is certified by the American Board of Surgery. He specializes in pancreatic, islet cell, and multi-organ transplants.

Dr. Odorico provides a wide range of services including Kidney Transplant, Pancreas Transplant.

Research Interests

Dr. Odorico’s research focuses on stem cell biology and differentiation, developing novel stem cell-based strategies for treating diabetes, pancreas transplantation, and islet cell transplantation.
Dr. Odorico’s lab

Clinical Trials

Conversion from Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of functional, safety and quality of life outcomes (CIRTEN SPK)
Study sponsor: University of Wisconsin-Madison
Study funding provided by: Veloxis Pharmaceuticals
Jon S. Odorico, MD, Principal Investigator
10/18/2018 –present

Non Invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-Derived Cell-free DNA in Peripheral Blood (PANCDx)
Study funding provided by: CareDx
Jon S. Odorico, MD, Sub-Investigator
Subcontract Agreement Amendment under negotiation, we expect to start enrollment in the first quarter of 2020

Recent Publications

  • Higher Fasting Pretransplant C-peptide Levels in Type 2 Diabetics Undergoing Simultaneous Pancreas-kidney Transplantation Are Associated With Posttransplant Pancreatic Graft Dysfunction.
    Parajuli S, Mandelbrot D, Aufhauser D, Kaufman D, Odorico J
    Transplantation 2023 Jan 05;
    [PubMed ID: 36706060]

  • Genetic Engineering of Immune Evasive Stem Cell-Derived Islets.
    Sackett SD, Kaplan SJ, Mitchell SA, Brown ME, Burrack AL, Grey S, Huangfu D, Odorico J
    Transpl Int 2022; 35: 10817
    [PubMed ID: 36545154]

  • Induction in Pancreas Transplantation: T-cell Depletion Versus IL-2 Receptor Blockade.
    Aziz F, Parajuli S, Kaufman D, Odorico J, Mandelbrot D
    Transplant Direct 2022 Dec; 8(12): e1402
    [PubMed ID: 36505900]

  • Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations.
    Kleiboeker HL, Descourouez JL, Schulz LT, Mandelbrot DA, Odorico JS, Rice JP, Saddler CM, Smith JA, Jorgenson MR
    Ann Pharmacother 2022 Aug 24; 10600280221118959
    [PubMed ID: 36003036]

  • CRISPR screening uncovers a central requirement for HHEX in pancreatic lineage commitment and plasticity restriction.
    Yang D, Cho H, Tayyebi Z, Shukla A, Luo R, Dixon G, Ursu V, Stransky S, Tremmel DM, Sackett SD, Koche R, Kaplan SJ, Li QV, Park J, Zhu Z, Rosen BP, Pulecio J, Shi ZD, Bram Y, Schwartz RE, Odorico JS, Sidoli S, Wright CV, Leslie CS, Huangfu D
    Nat Cell Biol 2022 Jul; 24(7): 1064-1076
    [PubMed ID: 35787684]

All Publications on PubMed